Securities Fraud Class Action Lawsuit Filed Against Talis Biomedical Corporation

CLICK HERE TO SUBMIT YOUR TALIS LOSSES

LIMIT FOR THE PLAINTIFF: March 8, 2022

LESSON: February 12, 2021 through January 7, 2022

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. (484) 270-1453 or duty free (844) 887-9500 or email [email protected]

SUCH ALLEGED MISCONDUCT
Talis develops diagnostic tests to enable accurate, reliable, cost-effective and rapid molecular testing for infectious diseases. In particular, the Talis One tests are being developed for respiratory infections, infections related to women’s health and sexually transmitted infections. In its registration statement, Talis has this in January 2021the Company has filed with the U.S. Food and Drug Administration (“FDA”) for an Emergency Use Authorization (“EUA”) for its Talis-One platform to conduct COVID-19 testing.

Then further March 8, 2021, Talis announced that it has withdrawn its EUA application for the Talis One COVID-19 test. In a press release, Talis announced that “[i]In late February, the FDA informed the company that it cannot ensure that the comparator assay used in the primary study has sufficient sensitivity to support Talis’ EUA application.” Following the news, Talis’ stock price fell $1.80, or 12% to close $12.85 per share March 8, 2021.

on August 10, 2021, Talis announced that its “development schedules have been extended due to delays in launch [Talis’] COVID-19 testing and production scale.” Talis’ share price fell on the news $0.58 per share, or 6%, at the end $8.39 per share August 11th, 2021. Then continue August 30, 2021, Talis announced the resignation of its Chief Executive Officer (“CEO”), Brian Coe. As a result of this news, Talis’ share price fell $1.00 per share or 11% at closing $8.06 per share August 31st, 2021. Finally further December 8, 2021, Talis announced Brian Blaser, who was appointed CEO on November 15, 2021He resigned from his position at Talis after just one week.

As a result, Talis’ share price fell $0.55 per share or 11.39% at close $4.28 per share December 8, 2021.

WHAT CAN I DO?
Talis investors can at the latest March 8, 2022, seek to be appointed lead plaintiff representative in the class action by Kessler Topaz Meltzer & Check, LLP or other counsel, or may elect to do nothing and remain an absentee class plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Talis investors who have suffered material losses to contact the company directly for more information.

CLICK HERE TO REGISTER FOR THE EVENT

Who can be a lead plaintiff?
A Lead Plaintiff is a representative party acting on behalf of all Group Members in conducting the litigation. The lead plaintiff is usually the investor or small group of investors who have the greatest financial interest and who are also appropriate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and class, and such attorneys, where permitted by the court, are principal or class counsel. Your ability to participate in a recovery will not be affected by the decision whether or not to serve as Lead Plaintiff.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
Kessler Topaz Meltzer & Check, LLP is pursuing class action lawsuits in state and federal courts across the country and around the world. The company has earned a global reputation for excellence, recovering billions of dollars from victims of fraud and other corporate wrongdoing. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, wrongdoing and negligence on the part of companies and fiduciaries. At the end of the day, if the bad guys pay and you get your fortune back, we’re done. The action in this lawsuit was not filed by Kessler Topaz Meltzer & Check, LLP. Additional information about Kessler Topaz Meltzer & Check, LLP is available at www.ktmc.com.

CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 König-von-Prussia-Strasse
Radnor, PA 19087
(844) 887-9500 (toll free)
[email protected]

SOURCE Kessler Topaz Meltzer & Check, LLP

Comments are closed.